Rapport Therapeutics Inc <RAPP.O>: William Blair initiates coverage with outperform rating
RAPP•Related News
GSK now expects 20+ phase III trial starts in 2026, up from 10
GSK•
Xylem raises annual profit forecast as AI growth lifts demand for water-treatment equipment
XYL•
Brookfield sees 6.5 GW of AI data-centre capacity coming online in India
BAM•
Vistra Corp <VST.N>: Raymond James cuts target price to $186 from $202
VST•
US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting
REPL•